Antiretroviral Drug Costs in Brazil
Author Information
Author(s): Amy Nunn, Elize M. Fonseca, Francisco I. Bastos, Sofia Gruskin, Joshua A. Salomon
Primary Institution: Harvard School of Public Health
Hypothesis
What are the drivers of recent antiretroviral drug cost trends in Brazil?
Conclusion
Brazil has saved approximately $1 billion on antiretroviral drugs since 2001, despite rising overall treatment costs.
Supporting Evidence
- Brazil's total drug expenditures on HAART doubled to $414 million in 2005.
- Negotiated prices for patented drugs in Brazil were lower than in other middle-income countries.
- Brazil's locally produced generic ARVs were generally more expensive than similar drugs made elsewhere.
- Price reductions for patented drugs saved Brazil approximately $1.2 billion from 2001 to 2005.
- Total costs would have been significantly lower if drug quantities had remained constant.
Takeaway
Brazil provides free HIV treatment, and while drug prices have dropped, the number of patients needing treatment has increased, leading to higher overall costs.
Methodology
The study analyzed drug-specific prices and expenditures for antiretroviral therapy in Brazil from 2001 to 2005.
Limitations
The study lacks data on patient regimen changes and does not account for price changes after 2005.
Participant Demographics
The study focuses on patients receiving highly active antiretroviral therapy (HAART) in Brazil.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website